Logo

Amgen Report Mixed Results of Omecamtiv Mecarbil in P-lll GALACTIC-HF Study for Heart Failure

Share this
Amgen Report Mixed Results of Omecamtiv Mecarbil in P-lll GALACTIC-HF Study for Heart Failure

Amgen Report Mixed Results of Omecamtiv Mecarbil in P-lll GALACTIC-HF Study for Heart Failure

Shots:

  • The P-lll GALACTIC-HF study involves the assessing of Omecamtiv mecarbil (25mg- bid with the maintenance dose of 50 mg- 37.5mg- or 25mg- bid) vs PBO in 8-256 patients with HFrEF
  • Result: The study met its 1EPs of reduction in CV death or HF events (HF hospitalization and other urgent treatment for HF) while the study did not meet its 2EPs of reduction in time to CV death- presented at AHA 2020
  • Omecamtiv mecarbil is a cardiac myosin activator- targeting the contractile mechanisms of the heart- being developed under a collaboration between Amgen and Cytokinetics- with funding and strategic support from Servier

     ­ Ref: Amgen | Image: The Times
Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions